First-Ever Personalized Cancer Vaccine Clears a Phase 3 Trial — A Milestone for Melanoma Patients

In mid-August 2026, Merck and Moderna announced that their experimental personalized mRNA cancer vaccine, intismeran autogene (also known as V940 or mRNA-4157), met its main goals in a large Phase 3 trial called INTerpath-001 when combined with the checkpoint inhibitor Keytruda (pembrolizumab) in patients with surgically removed, high-risk melanoma — the first time any individualized neoantigen cancer vaccine succeeded in a randomized Phase 3 trial. The full dataset will be unveiled at a Presidential Symposium at the ESMO Congress in Madrid on October 24, 2026.

Inside INTerpath-001

INTerpath-001 (NCT05933577) enrolled 1,137 patients with completely resected Stage IIB through IV cutaneous melanoma who had not yet received systemic therapy; randomized 2:1 to intismeran (every three weeks, up to nine doses) plus Keytruda, or Keytruda alone.

At a prespecified interim analysis, the trial met its primary endpoint, recurrence-free survival (RFS), and its key secondary endpoint, distant metastasis-free survival (DMFS); the safety profile was consistent with previously reported data with no new safety signals. Overall survival has not yet been reported.

Earlier Phase 2b Data

Earlier Phase 2b KEYNOTE-942 data (157 patients, five-year follow-up presented at ASCO 2026) showed roughly 49% reduction in recurrence or death risk and 59% in distant metastasis or death risk vs Keytruda alone — consistent in direction but not comparable hazard ratios/percentages for INTerpath-001 itself.

Regulatory Status

The companies plan to engage regulatory authorities about filing for approval, though no filing timeline has been announced; until the full data is presented and reviewed, the therapy remains fully investigational and not approved anywhere.

Caveats

Detailed Phase 3 statistics (actual benefit size, confidence intervals, event rates) are reserved for the October 24 ESMO presentation; overall survival data is unavailable from either trial; the 49%/59% figures come from the much smaller Phase 2b study; no confirmed submission date.

Bottom Line

The first individualized neoantigen cancer therapy to succeed in a randomized Phase 3 trial — a real and meaningful milestone — but the full data supporting it, including overall survival and the actual magnitude of benefit, will not be public until the October 24, 2026 ESMO Congress presentation, and the therapy remains investigational with no confirmed path or date to FDA approval yet.